225 related articles for article (PubMed ID: 25769931)
21. Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation.
Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D
J Cyst Fibros; 2015 Jan; 14(1):84-9. PubMed ID: 25049054
[TBL] [Abstract][Full Text] [Related]
22. Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation.
Zeybel GL; Pearson JP; Krishnan A; Bourke SJ; Doe S; Anderson A; Faruqi S; Morice AH; Jones R; McDonnell M; Zeybel M; Dettmar PW; Brodlie M; Ward C
J Cyst Fibros; 2017 Jan; 16(1):124-131. PubMed ID: 27475719
[TBL] [Abstract][Full Text] [Related]
23. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.
Flume PA; Liou TG; Borowitz DS; Li H; Yen K; Ordoñez CL; Geller DE;
Chest; 2012 Sep; 142(3):718-724. PubMed ID: 22383668
[TBL] [Abstract][Full Text] [Related]
24. Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.
Guimbellot JS; Baines A; Paynter A; Heltshe SL; VanDalfsen J; Jain M; Rowe SM; Sagel SD;
J Cyst Fibros; 2021 Mar; 20(2):213-219. PubMed ID: 33249004
[TBL] [Abstract][Full Text] [Related]
25. Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor.
Borowitz D; Lubarsky B; Wilschanski M; Munck A; Gelfond D; Bodewes F; Schwarzenberg SJ
Dig Dis Sci; 2016 Jan; 61(1):198-207. PubMed ID: 26250833
[TBL] [Abstract][Full Text] [Related]
26. Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation.
Trimble AT; Donaldson SH
J Cyst Fibros; 2018 Mar; 17(2):e13-e16. PubMed ID: 29079142
[TBL] [Abstract][Full Text] [Related]
27. Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients.
Moheet A; Beisang D; Zhang L; Sagel SD; VanDalfsen JM; Heltshe SL; Frederick C; Mann M; Antos N; Billings J; Rowe SM; Moran A;
J Cyst Fibros; 2021 Mar; 20(2):333-338. PubMed ID: 32917547
[TBL] [Abstract][Full Text] [Related]
28. Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T.
Carter S; Kelly S; Caples E; Grogan B; Doyle J; Gallagher CG; McKone EF
J Cyst Fibros; 2015 Jul; 14(4):e4-5. PubMed ID: 25698453
[TBL] [Abstract][Full Text] [Related]
29. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
30. In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis.
Sun X; Yi Y; Yan Z; Rosen BH; Liang B; Winter MC; Evans TIA; Rotti PG; Yang Y; Gray JS; Park SY; Zhou W; Zhang Y; Moll SR; Woody L; Tran DM; Jiang L; Vonk AM; Beekman JM; Negulescu P; Van Goor F; Fiorino DF; Gibson-Corley KN; Engelhardt JF
Sci Transl Med; 2019 Mar; 11(485):. PubMed ID: 30918114
[TBL] [Abstract][Full Text] [Related]
31. A little CFTR goes a long way: CFTR-dependent sweat secretion from G551D and R117H-5T cystic fibrosis subjects taking ivacaftor.
Char JE; Wolfe MH; Cho HJ; Park IH; Jeong JH; Frisbee E; Dunn C; Davies Z; Milla C; Moss RB; Thomas EA; Wine JJ
PLoS One; 2014; 9(2):e88564. PubMed ID: 24520399
[TBL] [Abstract][Full Text] [Related]
32. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
[TBL] [Abstract][Full Text] [Related]
33. Variability of sweat chloride concentration in subjects with cystic fibrosis and G551D mutations.
Vermeulen F; Le Camus C; Davies JC; Bilton D; Milenković D; De Boeck K
J Cyst Fibros; 2017 Jan; 16(1):36-40. PubMed ID: 26996268
[TBL] [Abstract][Full Text] [Related]
34. The effects of ivacaftor on CF fatty acid metabolism: An analysis from the GOAL study.
O'Connor MG; Seegmiller A
J Cyst Fibros; 2017 Jan; 16(1):132-138. PubMed ID: 27473897
[TBL] [Abstract][Full Text] [Related]
35. Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study.
Bell SC; Mainz JG; MacGregor G; Madge S; Macey J; Fridman M; Suthoff ED; Narayanan S; Kinnman N
BMC Pulm Med; 2019 Aug; 19(1):146. PubMed ID: 31409396
[TBL] [Abstract][Full Text] [Related]
36. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
[TBL] [Abstract][Full Text] [Related]
37. Positive clinical response to ivacaftor treatment in an individual with the CFTR genotype F508del/V456A.
Bratcher PE; Hunt KC; Pickard K; Taylor-Cousar JL
J Cyst Fibros; 2019 Mar; 18(2):e9-e10. PubMed ID: 30348612
[No Abstract] [Full Text] [Related]
38. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.
Heltshe SL; Mayer-Hamblett N; Burns JL; Khan U; Baines A; Ramsey BW; Rowe SM;
Clin Infect Dis; 2015 Mar; 60(5):703-12. PubMed ID: 25425629
[TBL] [Abstract][Full Text] [Related]
39. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.
Rowe SM; Heltshe SL; Gonska T; Donaldson SH; Borowitz D; Gelfond D; Sagel SD; Khan U; Mayer-Hamblett N; Van Dalfsen JM; Joseloff E; Ramsey BW;
Am J Respir Crit Care Med; 2014 Jul; 190(2):175-84. PubMed ID: 24927234
[TBL] [Abstract][Full Text] [Related]
40. Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment.
Edgeworth D; Keating D; Ellis M; Button B; Williams E; Clark D; Tierney A; Heritier S; Kotsimbos T; Wilson J
Clin Sci (Lond); 2017 Aug; 131(15):2037-2045. PubMed ID: 28611235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
